Tel:025-68136891, 17366374446  

Sign in  |  Register
中文  English
Location:Home » Education » Tutorial Introduction » Wei Jishu
Wei Jishu
Wei Jishu is a deputy chief physician, associate professor and master supervisor. He is now a Youth Committee Member of Surgery Branch of Jiangsu Province Medical Association, and a member of Young Scholars Climbing Plan of General Surgery of Chinese Journal of Practical Surgery. He has been to the University of Heidelberg for clinical visiting from March 2013 to September 2013.
Won the First Prize of 2016 Jiangsu New Medical Technology Award, and won the First Prize of 2014 Jiangsu New Medical Technology Award as the secondary contributor; won the First Prize of 2015 Jiangsu Provincial Award for Scientific and Technological Progress, the First Prize of Jiangsu Provincial Award for Medical Science and Technology, and the SecondPrize of China Award for Medical Scientific and Technological Progress as the ninth contributor; won the Second Prize of 2013 Ministry of Education Award for Scientific and Technological Progress as the second contributor.

Personnel programs and scientific research tasks involved

2016/08-2019/06. The person in charge of The Preliminary Study of the Effects of Denervation on the Occurrence and Progression of Pancreatic Cancer, a project of Jiangsu Provincial Natural Science Foundation;

2014/01-2016/12. The person in charge of The Experimental Study of Regional Injection of Type A Creotoxin for the Treatment of Pancreatic Cancer, a project of Jiangsu “Six Talented Personnel Summit”;

2013/01-2016/12. Participated in How Chronic Pancreatitis is Mediated by the Epithelial-Mesenchymal of Pancreatic Stellate Cell, a project of Natural Science Foundation of China;
2012/06-2017/01. Participated in the subsidiary subject of the Translational Medicine Study of the Early Diagnosis and Comprehensive Treatment of Pancreatic Cancer, an Industry Project of the Ministry of Health;

2012/01-2015/12. Participated in The Study of the Mechanism of the High Tolerance of the Bile Duct Cells of Rats Suffered from Liver Cirrhosis towards Ischemia, a project of Natural Science Foundation of China;2010/01-2012/12. Participated in the Study of the Mechanism of How the High Expression Galectin-1 of Pancreatic Stellate Cell Promotes Pancreatic Cancer Immunosuppression, a project of Natural Science Foundation of China;

2010/01-2012/12. Participated in the Study of the New Methods that Separates and Identifies the Stem Cells of Pancreatic Cancer and Relevant Biological Characteristics, a project of Natural Science Foundation of China;

2008/09-2013/01. Participated in the subsidiary topic of the Study of the Comprehensive Therapeutic System of Pancreatic Cancer, 2006BA102A13, a scientific and technological support plan of the 11th Five-Year Plan of the Ministry of Science and Technology.



1.   Wu J, Guo F, Wei J, et al. [Surgicaltreatment for pancreatic neuroendocrine neoplasmas]. Zhejiang da xue xue bao Yixue ban = Journal of Zhejiang University Medical sciences 2016; 45(1): 31-5.

2.   Wei J, Liu X, Wu J, et al. Diagnosis andsurgical management of insulinomas in 33 consecutive patients at a singleinstitution. Langenbeck's archives of surgery 2016; 401(7): 1019-25.

3.   Tu M, Lu C, Lv N, et al. Vasohibin 2 promoteshuman luminal breast cancer angiogenesis in a non-paracrine manner viatranscriptional activation of fibroblast growth factor 2. Cancer letters 2016;383(2): 272-81.

4.   Lu Z, Yin J, Wei J, et al. Small amounts oftissue preserve pancreatic function: Long-term follow-up study ofmiddle-segment preserving pancreatectomy. Medicine 2016; 95(46): e5274.

5.   Huo X, Wei J, Liu X, et al. Brunner's glandcyst in combination with gastrointestinal stromal tumor: A case report.Oncology letters 2016; 11(5): 3409-12.

6.   Gao W, Dai X, Dai C, et al. Comparison ofpatency rates and clinical impact of different reconstruction methods followingportal/superior mesenteric vein resection during pancreatectomy. Pancreatology: official journal of the International Association of Pancreatology (IAP)  [et al] 2016; 16(6): 1113-23.

7.   Wei J, Liu X, Wu J, et al. Modified One-layerDuct-to-mucosa Pancreaticojejunostomy Reduces Pancreatic Fistula AfterPancreaticoduodenectomy. International surgery 2015.

8.   Wei J, Lin S, Wang C, et al. Glucagonomasyndrome: A case report. Oncology letters 2015; 10(2): 1113-6.

9.   Ge Q, Zhou J, Tu M, et al. Nuclearvasohibin-2 promotes cell proliferation by inducing G0/G1 to S phase progression.Oncology reports 2015; 34(3): 1327-36.

10. Xue X, Zhang Y, Zhi Q, et al.MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumorsby inducing epithelial-mesenchymal transition in hepatocellular carcinoma. Cellcommunication and signaling : CCS 2014; 12: 62.

11. Tu M, Liu X, Han B, et al. Vasohibin2 promotesproliferation in human breast cancer cells via upregulation of fibroblastgrowth factor2 and growth/differentiation factor15 expression. Molecularmedicine reports 2014; 10(2): 663-9.

12. Wei J, Zheng L, Liu S, et al. MiR-196a2rs11614913 T > C polymorphism and risk of esophageal cancer in a Chinesepopulation. Human immunology 2013; 74(9): 1199-205.

13. Tang D, Wang D, Yuan Z, et al. Persistentactivation of pancreatic stellate cells creates a microenvironment favorablefor the malignant behavior of pancreatic ductal adenocarcinoma. Internationaljournal of cancer 2013; 132(5): 993-1003.

14. Sun J, Tu M, Han B, et al. Generation andcharacterization of rabbit polyclonal antibodies against Vasohibin-2 fordetermination of its intracellular localization. International journal ofoncology 2013; 43(1): 255-61.

15. Chen J, Li Q, An Y, et al. CEACAM6 inducesepithelial-mesenchymal transition and mediates invasion and metastasis inpancreatic cancer. International journal of oncology 2013; 43(3): 877-85.

16. Cai B, An Y, Lv N, et al. miRNA-181b increasesthe sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine invitro and in nude mice by targeting BCL-2. Oncology reports 2013; 29(5):1769-76.

17. An Y, Cai B, Chen J, et al. MAP3K10 promotesthe proliferation and decreases the sensitivity of pancreatic cancer cells togemcitabine by upregulating Gli-1 and Gli-2. Cancer letters 2013; 329(2):228-35.

18. Zhang Y, Wei J, Wang H, et al. Epithelialmesenchymal transition correlates with CD24+CD44+ and CD133+ cells inpancreatic cancer. Oncology reports 2012; 27(5): 1599-605.

19. Wang H, Wu J, Zhang Y, et al. Transforminggrowth factor beta-induced epithelial-mesenchymal transition increases cancerstem-like cells in the PANC-1 cell line. Oncology letters 2012; 3(1): 229-33.

20. Tang D, Yuan Z, Xue X, et al. High expressionof Galectin-1 in pancreatic stellate cells plays a role in the development andmaintenance of an immunosuppressive microenvironment in pancreatic cancer.International journal of cancer 2012; 130(10): 2337-48.

21. Chen M, Xue X, Wang F, et al. Expression andpromoter methylation analysis of ATP-binding cassette genes in pancreaticcancer. Oncology reports 2012; 27(1): 265-9.

22. Xue X, Lu Z, Tang D, et al. Galectin-1 secretedby activated stellate cells in pancreatic ductal adenocarcinoma stroma promotesproliferation and invasion of pancreatic cancer cells: an in vitro study on themicroenvironment of pancreatic ductal adenocarcinoma. Pancreas 2011; 40(6):832-9.

23. Wu J, Wei J, Meng K, et al. Identification ofan HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy.Immunopharmacology and immunotoxicology 2009; 31(3): 468-76.

24. Wei J, Gao W, Wu J, et al. Dendritic cellsexpressing a combined PADRE/MUC4-derived polyepitope DNA vaccine inducemultiple cytotoxic T-cell responses. Cancer biotherapy &radiopharmaceuticals 2008; 23(1): 121-8.